Floatz logo

cc-5013

Lymphomatoid Papulosis

John ReneauPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Lymphomatoid Papulosis cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Memorial Sloan Kettering Cancer Center
Phase 2B
Atlcar.Cd30.Ccr4 Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Bendamustine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Triamcinalone
Case Comprehensive Cancer Center
N/AD
Nitrogen Mustard
Case Comprehensive Cancer Center
N/AD
Bexarotene
Case Comprehensive Cancer Center
N/AD

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →